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Objectives. The purpose of this study was to prospectively
investigate the influence of ventricular fibrillation (VF) durations
of 5, 10 and 20 s on the defibrillation threshold (DFT) during
implantable cardioverter–defibrillator (ICD) implantation.
Background. Although the DFT using monophasic waveforms
has been shown to increase with VF duration in humans, the effect
of VF duration on defibrillation efficacy using biphasic waveforms
in humans is not known.
Methods. Thirty patients undergoing primary ICD implanta-
tion or pulse generator replacement were randomly assigned to
have the DFT determined using biphasic shocks at two durations
of VF each (5 and 10 s, 10 and 20 s or 5 and 20 s).
Results. There was no statistically significant difference in the
mean DFT comparing VF durations of 5 s (9.5 6 6.0 J) and 10 s
(10.8 6 7.0 J) (p 5 0.4). The mean DFT significantly increased
from 10.9 6 6.1 J at 10 s of VF to 12.6 6 5.6 J (p 5 0.03) at 20 s
of VF, and from 7.0 6 3.5 J at 5 s of VF to 10.5 6 6.3 J (p 5 0.04)
at 20 s of VF. An increase in the DFT was observed in 14 patients as
VF duration increased. There were no clinical characteristics that
differentiated patients with and without an increase in the DFT.
Conclusions. Defibrillation efficacy decreases with increasing
VF duration using biphasic waveforms in humans. Ventricular
fibrillation durations greater than 10 s may negatively affect the
effectiveness of ICD therapy.
(J Am Coll Cardiol 1999;33:33–8)
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Defibrillation efficacy is defined by a sigmoidal-shaped proba-
bility function with a gradual transition from unsuccessful to
successful shocks as the shock strength is increased rather than
by a discretely defined value (1–3). Although the mechanism
for the probabilistic nature of defibrillation remains unclear,
several factors have been identified that influence defibrillation
efficacy, including shock waveform and polarity (4–7), chronic-
ity of lead implantation (8,9), electrode size (10–12), location
(12–16), material (17) and geometry (18), drug therapy (15,19–
22) and heart and body weight (23–25).
The effect of ventricular fibrillation (VF) duration on
defibrillation efficacy is, however, not well established. Using
monophasic waveforms, Echt et al. reported an increase of the
defibrillation threshold (DFT) comparing VF durations of 5
and 30 s (26). In contrast, although Bardy et al. found no
change in defibrillation efficacy using monophasic waveforms
with VF duration of 10 and 20 s in humans during implantable
cardioverter–defibrillator (ICD) implantation (27), the same
group of investigators found an increase in the DFT after
unsuccessful monophasic first shocks (28).
Biphasic waveforms defibrillate with greater efficacy than
monophasic waveforms (29–32), and have largely replaced
other waveforms in contemporary devices. In isolated rabbit
hearts, biphasic waveforms provide lower energy and voltage
defibrillation thresholds than monophasic shocks at VF dura-
tions to 30 s, and the relative efficacy of biphasic shocks
improves with increasing VF duration (33). Furthermore, a
recent study examining the influence of VF duration using
biphasic waveforms in pigs reported a paradoxical decrease in
defibrillation energy with VF duration up to 20 s using biphasic
waveforms (34). However, the effect of VF duration on
defibrillation efficacy using biphasic waveforms has not been
studied in humans.
The effect of VF duration on defibrillation efficacy is of
particular importance, since current generation ICDs have
options for programming low energy cardioversion and anti-
tachycardia pacing that can lead to prolonged arrhythmia
duration before defibrillation. Thus, this study was designed to
investigate the influence of VF durations on defibrillation
efficacy using biphasic waveforms in humans.
Methods
Patient population. In accordance with institutional guide-
lines, written, informed consent was obtained from all patients
within a protocol approved by the Institutional Review Board
of the University of Alabama at Birmingham. Thirty patients
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undergoing primary ICD implantation or pulse generator
replacement were enrolled. Their demographic data are de-
scribed in Table 1. All patients who were thought able to give
consent and complete the protocol were approached. None
refused participation. There was one patient enrolled who did
not complete the protocol because his lead dislodged after the
first set of DFT tests. The protocol was not repeated after the
lead was repositioned.
According to a computer-generated random number se-
quence, patients were assigned to one of three groups with 10
patients in each. The DFT was determined twice in each
patient: at VF durations of 5 and 10 s in Group 1, 10 and 20 s
in Group 2 and 5 and 20 s in Group 3 (Fig. 1). Since the
primary aim of the operations was safe and successful ICD
implantation, VF durations of 5–10 s were tested first (in
accordance with usual practice) to assure a satisfactory DFT
for implantation. Thus, DFTs in Groups 1 and 2 were deter-
mined first at 10 s of VF, followed by a second determination
at 5 or 20 s of VF, respectively. In Group 3, DFTs were
determined first at 5 s of VF followed by a second determina-
tion at 20 s of VF.
Defibrillator implantation and defibrillation threshold
testing. All procedures were performed in the electrophysiol-
ogy laboratory of the University of Alabama at Birmingham.
General anesthesia with isoflurane was used in five patients
and intravenous sedation with midazolam and fentanyl in the
25 others. Electrocardiograms and electrograms were dis-
played online and recorded (Cardiolab, Prucka Engineering,
Houston, TX). Details of the implantation procedures are
summarized in Table 2.
Defibrillation threshold testing commenced after the defi-
brillation electrodes were appropriately positioned or, in the
case of previously implanted leads, after removal of the old
pulse generator. All testing was performed using an external
programmable defibrillator (HVS-02, Ventritex, Inc., Sunny-
vale, CA). All shocks were biphasic with equal first and second
phase durations, first and second phase capacitances of 150
and 300 mF respectively and leading edge voltages of the
second phase equal to 50% of the trailing edge voltage of the
first phase. After a low energy test shock was delivered to
measure the defibrillation system impedance, the pulse width
was optimized for the test shock impedance for further testing.
For each subsequent shock, the external defibrillator automat-
ically calculated the delivered energy in joules based on the
measured defibrillation system impedance.
Ventricular fibrillation was induced with burst pacing, and
diagnosed when the surface electrocardiogram was grossly
disorganized without clearly defined QRS complexes. Other
arrhythmias were not included in the analysis. Ventricular
fibrillation duration was defined as the time from the onset of
burst pacing to the delivery of the test shock, measured using
electronic calipers. The time of pacing was included in the VF
duration, since it allowed for easy timing of shock delivery, and
hemodynamic collapse always occurred during the pacing
train.
The first shock was given at a leading edge voltage of 400 V.
If unsuccessful, a high energy rescue shock was delivered. In
the case of successful defibrillation, the shock strength was
decremented by 100 V, and in the case of an unsuccessful
Abbreviations and Acronyms
DFT 5 defibrillation threshold
ICD 5 implantable cardioverter–defibrillator
VF 5 ventricular fibrillation
Figure 1. Description of the patient groups. VF 5 ventricular fibril-
lation.
Table 1. Demographics
Clinical Characteristic
Number
(%)
Number 30 (100)
Age (years) 61 6 12
Gender (male/female) 22/8 (73/27)
Left ventricular ejection fraction 0.32 6 0.12
Cardiac disease
Coronary artery disease 20 (67)
Dilated cardiomyopathy 5 (17)
Valvular heart disease 2 (6)
Arrhythmogenic right ventricular dysplasia 1 (3)
Idiopathic ventricular fibrillation 2 (6)
Presenting arrhythmia
Sustained ventricular tachycardia 17 (57)
Ventricular fibrillation 13 (43)
Antiarrhythmic drug therapy
Amiodarone 6 (20)
Sotalol 1 (3)
Table 2. Implantation Procedures
Procedure Patients
Primary ICD implantation 21
ICD generator replacement 9
Endocardial leads 21
Endocardial leads and subcutaneous patch electrode 2
Epicardial leads 7
Pectoral pocket 20
Abdominal pocket 10
General anesthesia 5
Conscious sedation 25
ICD 5 implantable cardioverter–defibrillator.
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shock increased by 100 V until an outcome reversal was
observed. After the first outcome reversal, the shock strength
was increased by 50 V if the prior shock had failed to
defibrillate, or decreased by 50 V if the prior shock was
successful. The DFT was defined as the lowest shock energy
resulting in successful defibrillation. Each VF induction and
defibrillation sequence was separated by a minimum of 5 min.
After the DFT was determined for one VF duration, the
procedure was repeated in identical fashion for the second VF
duration.
Statistical analysis. Continuous variables were expressed
as mean 6 1 SD. Nominal variables were compared by
chi-square analysis. Paired data were compared using the
Wilcoxon Signed Rank Test. Unpaired data were compared
using simple regression analysis. Statistical significance was
defined as p , 0.05.
Results
Paired comparison of DFT at VF durations of 5, 10 and
20 s. The defibrillation threshold data for voltage, energy and
impedance are summarized in Table 3. For patients in Group
1, the DFT of 9.5 6 6.0 J (365 6 108 V) at 5 s of VF was not
different from the DFT of 10.8 6 7.0 J (385 6 131 V) at 10 s
of VF (p 5 0.4, Fig. 2). For patients in Group 2, the DFT
increased by 16% from 10.9 6 6.1 J (390 6 113 V) at 10 s of
VF to 12.6 6 5.6 J (425 6 107 V) at 20 s of VF (p 5 0.03, Fig.
3). Similarly, for patients in Group 3, the DFT increased by
50% from 7.0 6 3.5 J (320 6 86 V) after 5 s of VF to 10.5 6
6.3 J (385 6 118 V) after 20 s of VF (p 5 0.04, Fig. 4). Thus,
although there was no difference in the DFT at 5 and 10 s of
VF, energy requirements significantly increased at 20 s com-
pared with both 5 and 10 s of VF.
Unpaired comparison of DFT at VF durations of 5, 10 and
20 s. The mean DFT increased from 8.3 6 4.9 J at 5 s of VF
to 10.8 6 6.4 J and 11.5 6 6.0 J at 10 and 20 s of VF,
respectively (p 5 0.08, Fig. 5). The mean number of DFT
tests/VF inductions done for the 5-, 10- and 20-s groups (20
tests for each) were 4.3 6 1.3 (range 3 to 9), 5.0 6 1.9 (range
3 to 10) and 5.1 6 1.6 (range 3 to 10), respectively.
With increasing VF duration, the DFT increased by at least
1 J in 14 patients (47%), remained unchanged in 14 patients
and decreased in 2 patients. Clinical characteristics did not
predict DFT changes (Table 4). In Group 1, the DFT increased
in four patients from 8.3 6 3.1 J (350 6 71 V) to 12.4 6 6.1 J
(425 6 104 V) (p 5 0.07), remained unchanged in five patients
at 11.2 6 8.0 J (390 6 143 V), and decreased in one patient
from 6 J (300 V) to 2.6 J (200 V). In Group 2, the DFT
increased in four patients from 7.6 6 2.2 J (338 6 48 V) to
12.0 6 3.6 J (425 6 65 V) (p 5 0.07) and remained unchanged
in six patients (13.0 6 7.0 J, 425 6 135 V). In Group 3 the DFT
increased in six patients from 7.5 6 4.5 J (325 6 113 V) to
14.0 6 5.8 J (450 6 110 V) (p 5 0.03), remained unchanged in
three patients (6.4 6 1.2 J, 317 6 29 V) and decreased in one
patient from 7.8 J (350 V) to 5.7 J (300 V).
Discussion
This study demonstrates that defibrillation efficacy using
biphasic waveforms decreases with increasing VF duration in
humans. Although there was no difference in the DFT at 5 and
10 s of VF, the DFT increased significantly at 20 s compared
Figure 2. Change in the defibrillation threshold energy at ventricular
fibrillation (VF) durations of 5 and 10 s. Figure 3. Change in the defibrillation threshold energy at ventricular
fibrillation (VF) durations of 10 and 20 s.
Table 3. Defibrillation Threshold Data
Group 1 Group 2 Group 3
5-s VF 10-s VF p Value 10-s VF 20-s VF p Value 5-s VF 20-s VF p Value
Energy (J) 9.5 6 6.0 10.8 6 7.0 0.40 10.9 6 6.1 12.6 6 5.6 0.03 7.0 6 3.5 10.5 6 6.3 0.04
Voltage (V) 365 6 108 385 6 131 0.34 390 6 113 425 6 107 0.07 320 6 86 385 6 118 0.05
Impedance (ohms) 49.7 6 8.7 50.4 6 9.4 0.25 49.1 6 7.6 48.7 6 9.1 0.58 57.8 6 16.0 55.7 6 16.4 0.07
VF duration (s) 5.6 6 0.4 9.9 6 0.5 — 10.2 6 0.7 20.0 6 0.5 — 5.5 6 0.3 19.8 6 0.4 —
VF 5 ventricular fibrillation.
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with both 5 and 10 s of VF. The increase of the mean DFT was
a modest 16% comparing VF durations of 10 and 20 s, but
increased by 50% comparing VF durations of 5 and 20 s.
Despite these VF duration–dependent changes in DFT, an
appropriate safety margin to allow implantation of the device
was demonstrated in all patients.
Although the VF duration–dependent increase in DFT was
observed in 14 of 30 patients, it remained unchanged in 14 and
decreased in 2. Thus, rather than a gradual VF duration–
dependent increase in DFT in all patients, the DFT did not
change in about half of the patients and increased substantially
in the other half. In those patients with an increased DFT, the
changes were large, with a mean increase of 49% (8.3 J vs. 12.4 J)
comparing 5 and 10 s, 58% (7.6 J vs. 12.0 J) comparing 10 and 20 s
and 87% (7.5 J vs. 14.0 J) comparing 5 and 20 s. Clinical
variables did not predict which patient would exhibit a VF
duration–dependent increase in DFT.
Previous studies. The effect of VF duration on defibrilla-
tion efficacy has been previously investigated in various species
at several VF durations using different waveforms and exper-
imental designs that may have resulted in discordant findings.
Thus, for monophasic waveforms, as VF duration increases,
the DFT has been reported to increase in dogs (26) and
humans (35,36), and to remain unchanged in pigs (37), dogs
(38) and humans (27). Bardy et al. compared the efficacy of
monophasic waveforms during ICD implantation via thoracot-
omy or pulse generator replacement in 10 patients and found
no difference in DFT at 10 and 20 s of VF (27). The same
investigators have also shown that an unsuccessful monophasic
first shock was associated with a 61% increase in the DFT for
the second shock (28). It was hypothesized that the time
difference between VF termination with (28 6 6.2 s) and
without (12.4 6 3.5 s) a first unsuccessful shock may have been
responsible for this difference. Winkle et al. reported higher
defibrillation efficacy at 5 than 15 s of VF using monophasic
waveforms (35). Platia et al. found that for monophasic shocks,
prolonging VF duration from 5 to 15 and to 25 s increased the
DFT from 7 6 4 to 13 6 4 and 23 6 8 J, respectively (36).
Biphasic waveforms have replaced monophasic waveforms
in contemporary ICDs due to their superior defibrillation
efficacy (4,10,29,33,39) and less traumatic effects on cardiac
tissue (31,32,40). The mechanism responsible for the increased
efficacy is not known. It has been hypothesized that biphasic
waveforms require a lower potential gradient field for success-
ful defibrillation (41), are less (42) or more (43) able to excite
refractory myocardium and are less likely to cause conduction
block and reentry in high potential gradient areas (44).
The effect of VF duration on defibrillation efficacy using
biphasic waveforms was first reported by Jones et al. using an
isolated rabbit heart model (33). Although defibrillation en-
ergy requirements increased for monophasic waveforms in this
study, the mean DFT remained unchanged for biphasic wave-
forms at 5, 15 and 30 s of VF. The investigators speculated that
the stabilizing effect of biphasic waveforms on defibrillation
requirements was a result of the first phase of the waveform
causing recovery of excitation channels in depolarized, par-
tially refractory ventricular cells. In a recent study examining
the effect of VF duration in pigs using biphasic waveforms, a
paradoxical decrease of defibrillation requirements was ob-
served at 20 s compared with 10 s of VF (34).
The present study is the first to investigate defibrillation
efficacy of biphasic waveforms at different VF durations in
humans. In contrast to the experimental data in animals,
defibrillation requirements increased significantly beyond 10 s
of VF. This difference may be the result of interspecies
differences, or because of differences in the arrhythmia sub-
Figure 4. Change in the defibrillation threshold energy at ventricular
fibrillation (VF) durations of 5 and 20 s.
Figure 5. Grouped data for the defibrillation threshold energy for all
patients (20 each tested at 5, 10 and 20 s of ventricular fibrillation [VF],
respectively).
Table 4. Influence of Clinical Characteristics of Defibrillation
Threshold
Increase
in DFT
No Change
in DFT p
Patients (n) 14 16 NS
Age (yr) 58 6 14 63 6 10 NS
Gender (male/female) 9/5 13/3 NS
Left ventricular ejection fraction 0.36 6 0.15 0.29 6 0.09 NS
Cardiac disease
Coronary artery disease 8 12 NS
Dilated cardiomyopathy 2 3 NS
Presenting arrhythmia
Sustained ventricular tachycardia 7 10 NS
Ventricular fibrillation 7 6 NS
Amiodarone therapy 3 3 NS
DFT 5 defibrillation threshold.
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strate and experimental design. Furthermore, a stabilizing
effect of biphasic waveforms on DFT in humans at VF
durations beyond 20 s cannot be excluded, since they were not
investigated in this study. However, our data are in concert
with the VF duration–dependent increase in the DFT using
monophasic waveforms in humans reported by Winkle et al.
(35) and Platia et al. (36), and with their observations of high
defibrillation efficacy at particularly short (5-s) VF durations.
Limitations. There are several limitations to the present
study. First, there was considerable variation in lead configu-
ration, chronicity of the implanted leads and pulse generator
location. However, since each patient served as his own
control, the potential for error was minimized. Second, the
influences of general anesthesia and intravenous sedation on
autonomic tone and the DFT are unknown. However, the use
of anesthesia and sedation conforms to standard practice.
Third, only biphasic waveforms were used in this study. The
influence of VF duration on the DFT when other waveforms
are used is unknown.
Fourth, VF was induced in this study by burst pacing. There
are various methods to induce VF, including alternating cur-
rent, T wave shocks and burst pacing, and their impact on the
DFT is not known. However, it is conceivable that each
method results in a different form of VF with various numbers
of activation fronts and cycle lengths that may change with
time, and therefore, have influence on defibrillation efficacy.
Fifth, defibrillation at 20 s always followed testing after
determination of the DFT at 5 or 10 s, which might have biased
the results against the 20-s tests. However, this approach was
chosen because the primary purpose of the procedure was to
implant an ICD, and testing more traditional VF durations to
establish defibrillation efficacy allowed this determination to be
made before the investigation portion of the study was under-
taken. It is impossible to know just how much of an effect the
performance of this order of testing had on the study results.
Sixth, the present study does not provide evidence for the
mechanism responsible for the increased defibrillation energy
requirement when VF duration is prolonged. Possible expla-
nations include increased ischemia that results in extra- and
intracellular metabolic derangements, changes in the myocar-
dial cell membrane, an increase in heart size due to diastolic
filling that decreases defibrillation efficacy (45) and evolution-
ary changes of VF characteristics, such as VF cycle length and
number and size of activation fronts at the time of shock
delivery. Finally, no longitudinal follow-up was performed to
assess the reproducibility of the findings.
Clinical implications. The observations made in the
present study have several theoretical and practical implica-
tions related to DFT testing and programming of contempo-
rary ICD devices. First, VF duration during DFT determina-
tion should be standardized, at least in research protocols, to
insure comparability of results between studies and individual
patients. If both the energy and VF duration change during
testing, the results will reflect not only the change in energy but
also the change in VF duration.
Second, although device-based DFT testing is a practical
method to assess defibrillation efficacy, the defibrillation en-
ergy requirement determined by this method will depend on
not only shock strength but also the arrhythmia detection time
and charge time of the device being tested. For example, very
high shock strengths that require long charging times (such as
20 s as tested in this study) will shift the probability of success
curve toward higher values, whereas low shock strengths
having short charging times (,5 s) will shift the probability of
success curve toward lower values. Although this may mimic
the real-life situation at the beginning of ICD battery life, the
term “DFT” in the context of device-based testing is a relative,
and potentially misleading term, since as ICD batteries age and
charge times prolong, more energy may be needed to defibril-
late. Although this may be less relevant to most patients in this
era of declining DFTs, the occasional patient with a high DFT
at the time of implantation may not have a sufficient safety
margin to ensure reliable defibrillation during long-term
follow-up (46). Furthermore, for patients with a high DFT and
narrow margin of safety for defibrillation, interventions that
prolong arrhythmia duration before shock therapy, such as
antitachycardia pacing and/or low energy cardioversion, prob-
ably should be avoided in the interest of reliable defibrillation.
Finally, the upper limit of vulnerability has been shown to
correlate with the DFT in both animals and humans (47–50).
An advantage of using the upper limit of vulnerability to
determine defibrillation efficacy at ICD implantation is the
need for fewer episodes of VF to be tested. Another potential
advantage of the upper limit of vulnerability is its indepen-
dence of VF duration. However, if clinical efficacy in the field
depends in part on VF duration, the upper limit of vulnerabil-
ity may not be as useful as the DFT to establish adequate
margins of safety for defibrillation. Furthermore, since com-
parison of the upper limit of vulnerability with the DFT has
usually been done at predetermined VF durations, the corre-
lation between the DFT and the upper limit of vulnerability
may be less if different durations were studied.
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